Open Call SMEInst-06-2016-2017: Accelerating Market Introduction of ICT Solutions for Health, Well-Being and Ageing Well

European CommissionThe healthcare biotechnology sector offers huge business and commercial opportunities; however it also requires heavy and risky investments which are often lacking in Europe, hampering the development of the industry. The SME instrument consists of three phases, including a coaching and mentoring service for beneficiaries. Participants can apply to phase 1 or directly to phase 2.

In phase 1, a feasibility study shall be developed in order to verify the technological/practical as well as economic viability of an innovation idea/concept with considerable novelty to the industry sector in which it is presented (new products, processes, design, services and technologies or new market applications of existing technologies). The activities could, for example, comprise risk assessment, market study, user involvement, Intellectual Property (IP) management, innovation strategy development, partner search, feasibility of concept and the like to establish a solid high-potential innovation project aligned to the enterprise strategy and with a European dimension. Bottlenecks in the ability to increase profitability of the enterprise through innovation shall be detected and analysed during phase 1 and addressed during phase 2 to increase the return in investment in innovation activities. The proposal should contain an initial business plan based on the proposed idea/concept. It should outline the specifications of a more elaborate business plan, which is to be the outcome of the project, and the criteria for success.

Funding will be provided in the form of a lump sum of EUR 50.000. Projects should last around 6 months.

In phase 2, innovation projects will be supported that address the specific challenges identified and that demonstrate high potential in terms of company competitiveness and growth underpinned by a strategic business plan. Activities should focus on innovation activities such as demonstration, testing, prototyping, piloting, scaling-up, miniaturisation, design, market replication and the like aiming to bring an innovation idea (product, process, service etc.) to industrial readiness and maturity for market introduction, but may also include some research.

Proposals shall be based on an elaborate business plan. Particular attention must be paid to IP protection and ownership; applicants will have to present convincing measures to ensure the possibility of commercial exploitation ('freedom to operate').

Proposals shall contain a specification for the outcome of the project and criteria for success. They will include an explanation of how the results of the supported project are to be commercialised and of what kind of impact on the company is expected.

The Commission considers that proposals requesting a contribution from the EU of between EUR 0.5 and 2.5 million.

Phase 3 of the SME Instrument aims to increase the economic impact of the funding provided by the SME Instrument phase 1&2 grants and by the business coaching. Phase 3 is not subsequent to phase 1 and/or 2, but provides specific support to SME instrument beneficiaries during and after phase 1 or 2.

Types of action: SME-1 SME instrument phase 1

Cut-off dates (Brussels time):
24 February 2016 17:00:00
03 May 2016 17:00:00
07 September 2016 17:00:00
09 November 2016 17:00:00
15 February 2017 17:00:00
03 May 2017 17:00:00
06 September 2017 17:00:00
08 November 2017 17:00:00

Types of action: SME-2 SME instrument phase 2

Cut-off dates (Brussels time):
03 February 2016 17:00:00
14 April 2016 17:00:00
15 June 2016 17:00:00
13 October 2016 17:00:00
18 January 2017 17:00:00
06 April 2017 17:00:00
01 June 2017 17:00:00
18 October 2017 17:00:00

For topic conditions, documents and submission service, please visit:
http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/h2020/topics/6117-smeinst-05-2016-2017.html

Find your partners or consortia preparing a project proposal
If you need help to identify a potential partner or consortia with particular competences, facilities or experience, please join Health IT Space at http://www.healthitspace.eu

Health IT Space is the first social networking platform for Health IT Professionals and Stakeholders. Explore the list of all Health IT Space registered members at http://www.healthitspace.eu/network/members

Most Popular Now

Elsevier Adds to its Extensive Free Reso…

Elsevier, a global leader in information analytics specializing in science and health, is offering free access to a unique set of biomedical research tools and content to help researchers and...

Cancer Care Model could Help Us Cope wit…

As the UK government looks for an exit strategy to Britain's COVID-19 lockdown a nanomedicine expert from The University of Manchester believes a care model usually applied to cancer patients...

An EU Approach for Efficient Contact Tra…

EU Members States, supported by the Commission, have developed an EU toolbox for the use of mobile applications for contact tracing and warning in response to the coronavirus pandemic. This...

New AI Diagnostic can Predict COVID-19 w…

Researchers at King's College London, Massachusetts General Hospital and health science company ZOE have developed an artificial intelligence diagnostic that can predict whether someone is likely to have COVID-19 based...

COVID-19 and Health Tech: Building on th…

Highland Marketing's advisory board met to discuss the health tech response to the coronavirus outbreak. In many areas, this has been hugely impressive: but there are gaps, and there will...

Biomax Provides AI-Based Semantic Search…

The bioinformatics company Biomax, headquartered in Planegg, Germany, makesitssemantic search platform AILANI available free of charge to research institutes around the world in order to support the rapid and successful...

InsurTech Hub Munich and dmac/Digital He…

InsurTech Hub Munich (ITHM) and dmac - Medical Valley Digital Health Application Center part of the Digital Health Hub Nuremberg/Erlangen announce a new cross-industry accelerator for the second half of...

Telemedicine Transforms Response to COVI…

A rapid increase in "virtual" visits during the COVID-19 pandemic could transform the way physicians provide care in the United States going forward, according to a new study led by...

Viveo Health Offers Free Telemedicine So…

Viveo Health, a global e-Health innovator, is making its 'Virtual Office for Doctors' platform free of charge to doctors and other medical professionals worldwide in light of the surge in...

Supercomputer Simulations Present Potent…

Several drugs approved for treating hepatitis C viral infection were identified as potential candidates against COVID-19, a new disease caused by the SARS-CoV-2 coronavirus. This is the result of research...

The Dedalus Group, Participated by Ardia…

The Dedalus Group, a leading European company, and one of the worldwide main ones, active in clinical healthcare information systems to support clinical professionals and organizations in order to improve...

The COVID-19 pandemic reveals the potent…

Two new articles provide insights on the use of telehealth or virtual care in the age of COVID-19 and beyond, pointing to its value to not only prevent contagious diseases...